Stock Ticker

  • Loading stock data...

Novavax, Inc. (NASDAQ:NVAX) Publishes Study for RSV-F Vaccine and Schedules Investor Meeting

Novavax, Inc. (NASDAQ:NVAX) has announced that it would be hosting its “3rd Annual Analyst and Investor conference”, on September 29, 2015 in New York. Furthermore, the company has also revealed that its guinea pig trials, focused on maternal immunization, have been observed to be highly immunogenic. The results of the study have been published in the journal “Vaccine”. The trial made use of RSV-F protein recombinant nano-particles, which is amongst the clinical stage vaccines under development by Novavax.

Novavax has been developing the RSV-F vaccine to provide immunity to infants against RSV. However, the major problem that the company needed to counter was the method of delivery. Direct immunization tends to create problems, in the case of infants, due to premature immune systems. The initial trials, on guinea pigs, had been focused on providing immunization to the infants, while still in the uterus.

The senior VP of Research and Development at Novavax, Gregory M. Glenn, stated that RSV is amongst the leading unmet needs in infants. He also pointed out that the guinea pigs were chosen as subjects, since their placental architecture is the closest to that of humans. The VP also hinted at the results from the phase-2 trials might be released by the end of this quarter. Further details about the development of this vaccine and others are expected to be revealed during the conference in New York. It is also expected that an opinion leader would also be called in to provide his perspective on RSV and the new vaccine.

While the majority of analysts have awarded the company a buy rating, Zacks has ranked NVAX as a hold for the short term. Furthermore, NVAX has also revealed insider selling, conducted by a director, Evans Gary. A total of 20,000 shares were sold by Gary, at an average share price of $11.24 on August 24, 2015. At the moment, only 0.5% of the company is owned by insiders.

Novavax, Inc. (NASDAQ:NVAX) completed the September 22 session, with a loss of 1.41% to its share value, to close at a share price of $9.77.

Published by Donna Fago

I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.

  • Recent Stories

    SignUp Now For Our Featured Newsletter

    Sign Up To Get Our Latest Stocks Alerts